Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Applied Therapeutics Inc APLT

Healthcare Biotechnology
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare... see more

Recent & Breaking News (NDAQ:APLT)

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

GlobeNewswire 6 hours ago

Applied Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference

GlobeNewswire November 5, 2024

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

GlobeNewswire September 18, 2024

Applied Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 4, 2024

Applied Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire August 7, 2024

Applied Therapeutics Added to Russell 3000® Index

GlobeNewswire July 1, 2024

Applied Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire May 9, 2024

Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2024

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

GlobeNewswire April 15, 2024

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

GlobeNewswire April 4, 2024

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

GlobeNewswire March 28, 2024

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

GlobeNewswire March 6, 2024

Applied Therapeutics Announces $100 Million Private Placement

GlobeNewswire February 28, 2024

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia

GlobeNewswire February 28, 2024

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

GlobeNewswire February 15, 2024

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

GlobeNewswire January 4, 2024

Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia

GlobeNewswire January 3, 2024

Applied Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

GlobeNewswire November 2, 2023